Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

v3.19.3.a.u2
Accrued Expenses
9 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
Accrued Expenses

Accrued expenses are composed of the following at December 31, 2019 and March 31, 2019:

 

    December 31,   March 31,
    2019   2019
         
 Accrued expenses for AV-101, PH94B, and PH10                
      clinical trial, development and related expenses   $ 876,600     $ 1,067,600  
 Accrued compensation     —         439,200  
 Accrued professional services     66,800       172,100  
 All other     7,900       6,700  
    $ 951,300     $ 1,685,600